ALAB vs CLS: which is the better buy in 2026?
On Alexandria's Compass, Astera Labs, Inc. has the edge with a 94/100 score versus 93/100 for CLS. Here is how they stack up, factor by factor.
Astera Labs, Inc.
NASDAQ:ALAB
The connectivity tax on every AI rack is real, but you're paying for three years of perfect execution at today's price.
Full ALAB analysisCelestica Inc.
NYSE:CLS
The hyperscaler's favourite hardware partner has graduated from contract manufacturer to AI infrastructure designer, and the multiple still doesn't reflect it.
Full CLS analysisFactor by factor
Get head-to-heads like this, free
Join the Alexandria e-letter for Compass verdicts, earnings intelligence, and the contrarian calls the crowd misses. Twice a week, no noise.
Free forever. Unsubscribe anytime. We never share your email.
Frequently asked questions
Is ALAB or CLS the better buy in 2026?
By Compass Score, Astera Labs, Inc. (NASDAQ:ALAB) edges it at 94/100 versus 93/100 for CLS. Both scores update weekly and reflect a contrarian, forward-looking read, not a recommendation.
How does Alexandria compare ALAB and CLS?
Each company is scored 1-100 on eight factors: revenue growth, profitability, valuation, momentum, theme purity, moat, catalysts, and market position. The Compass Score is the composite, and the comparison below shows where each name wins factor by factor.
Compass Scores are proprietary editorial research from publicly available data, not investment advice or a recommendation regarding any security. Rankings update weekly.